Unique ID issued by UMIN | UMIN000013304 |
---|---|
Receipt number | R000015088 |
Scientific Title | Phase I study of concurrent chemoradiotherapy with docetaxel,cisplatin and 5-fluorouracil (DCF) in patients with locally advanced cancer of the external auditory canal and middle ear. |
Date of disclosure of the study information | 2014/03/01 |
Last modified on | 2014/01/20 22:25:03 |
Phase I study of concurrent chemoradiotherapy with docetaxel,cisplatin and 5-fluorouracil (DCF) in patients with locally advanced cancer of the external auditory canal and middle ear.
Phase I study of CCRT with DCF for advanced ear cancer
Phase I study of concurrent chemoradiotherapy with docetaxel,cisplatin and 5-fluorouracil (DCF) in patients with locally advanced cancer of the external auditory canal and middle ear.
Phase I study of CCRT with DCF for advanced ear cancer
Japan |
Neoplasm of the external auditory canal and middle ear
Hematology and clinical oncology | Oto-rhino-laryngology | Radiology |
Malignancy
NO
to evaluate the safety of concurrent chemoradiotherapy with docetaxel,cisplatin and 5-fluorouracil (DCF) in patients with locally advanced cancer of the external auditory canal and middle ear.
Safety
Exploratory
Phase I
Maximum tolerated dose and recommended dose
frequency and severity of side effects
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine |
Concurrent chemoradiotherapy
docetaxel 40-60 mg/m2/day day1 iv
cisplatin 70 mg/m2/day day1 iv
5-fluorouracil 700 mg/m2/day day1-5 civ
q4w , 2 cycle
RT 66Gy/33fr/7w
Radiotherapy starts on day1.
20 | years-old | <= |
75 | years-old | >= |
Male and Female
1) Histologically proven squamous cell carcinoma of the external auditory canal or middle ear
2) Primary lesion is located in the external auditory canal or middle ear
3) With T3 and T4 tumors in Pittsburgh tumor staging system (modified in 2000)
4) Patients with T3 tumors rejecting operation
5) No previous treatment of ear cancer without excisional biopsy or unresectable reccurrent tumor
6) No distant organ metastases
7) Aged 20 to 75 years old
8) ECOG PS of 0 or 1
9) No previous radiotherapy in head and neck lesion or radiologist permits curative additional radiotherapy
10) No previous chemotherapy within three years
11) Adequate organ functions
12) Written informed consent
1) Pregnant or lactating women or women of childbearing potential
2) Psychosis
3) Patients requiring systemic steroids medication
4) HBs antigen positive
5) HCV antibody positive
6) HIV antibody positive
7) Uncontrollable diabetes millutus
8) History of myocardial infarction within three months
9) History of unstable angina pectoris or interstitial pneumonia or fibroid lung or severe emphysema
10) Active bacterial or fungous infection
11) In case of judge as inadequate subjects by attending physician
12
1st name | |
Middle name | |
Last name | Shingo Hasegawa, M.D, PhD |
Kobe University Hospital
Otolaryngology-Head & Neck Surgery
7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017 JAPAN
0783825111
shingo@med.kobe-u.ac.jp
1st name | |
Middle name | |
Last name | Shingo Hasegawa, M.D, PhD |
Kobe University Hospital
Otolaryngology-Head & Neck Surgery
7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017 JAPAN
0783825111
shingo@med.kobe-u.ac.jp
Kobe University Hospital
none
Self funding
NO
2014 | Year | 03 | Month | 01 | Day |
Unpublished
Preinitiation
2014 | Year | 02 | Month | 28 | Day |
2014 | Year | 03 | Month | 01 | Day |
2014 | Year | 02 | Month | 28 | Day |
2014 | Year | 01 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015088
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |